Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05691699 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
NCT05691699 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 104 participants.
The verdict
NCT05691699, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate adverse events and tolerability of single and multiple doses of ABBV-903, and to assess how the drug moves through the body in healthy adult volunteers.
Interventions
- DRUG Itraconazole
- DRUG ABBV-903
- DRUG Placebo for ABBV-903
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2023-01-03 |
| Est. Completion | 2023-10-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05691699
The ClinicalTrials.gov registry entry for NCT05691699 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Itraconazole is the first listed.
NCT05691699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05691699 about?
NCT05691699 is a clinical study titled "A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults". The purpose of this study is to evaluate adverse events and tolerability of single and multiple doses of ABBV-903, and to assess how the drug moves through the body in healthy adult volunteers.
What is the current status of trial NCT05691699?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2023-01-03. Estimated completion is 2023-10-23.
What interventions are being tested in trial NCT05691699?
The interventions under investigation include: Itraconazole (DRUG), ABBV-903 (DRUG), Placebo for ABBV-903 (DRUG).
Who is sponsoring clinical trial NCT05691699?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.